Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00206635
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : November 22, 2012
Information provided by:

September 9, 2005
September 21, 2005
November 22, 2012
January 2005
Not Provided
Description of long term course of disease [ Time Frame: 16 years ]
Not Provided
Complete list of historical versions of study NCT00206635 on Archive Site
Comparison to natural history cohort [ Time Frame: 16 years ]
Not Provided
Not Provided
Not Provided
Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis
A Long-term Follow up of Patients Enrolled in the Pivotal Study of Betaseron® (Interferon Beta 1b) in Relapsing-remitting Multiple Sclerosis
The purpose of this follow-up study is to look carefully at the long-term course of multiple sclerosis (MS) and possibly the long-term effects of Betaseron in the patients who were previously enrolled in the original North American study that led to the marketing approval of Betaseron.
This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc. is the sponsor of the trial.
Observational Model: Cohort
Time Perspective: Cross-Sectional
Not Provided
Retention:   Samples With DNA
Whole blood, serum
Non-Probability Sample
Original pivotal trial population of Betaseron pivotal study (1989-1993)
Multiple Sclerosis
Drug: Interferon beta-1b (Betaseron, BAY86-5046)
Betaseron was not administered as part of this study, only the treatment and disease status was assessed. As part of the MRI analysis Gadolinium was administered in patients who underwent this procedure
Group 1
Intervention: Drug: Interferon beta-1b (Betaseron, BAY86-5046)

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
December 2005
Not Provided

Inclusion Criteria:

  • Patients in North America have to have been previously enrolled in the original Betaseron trial from 1988-1993
  • Be able to understand the consent form (or have a guardian who can)

Exclusion Criteria:

  • North American patients cannot be included if they have not participated in the original Betaseron trial from 1988-1993
Sexes Eligible for Study: All
33 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Canada,   United States
United Kingdom
Not Provided
Not Provided
Medical Affairs Therapeutic Area Head, Bayer Healthcare Pharmaceuticals Inc.
Not Provided
Study Director: Bayer Study Director Bayer
November 2012